Search results
Results from the WOW.Com Content Network
[13] [16] There are far fewer studies evaluating the side effects of 5α-reductase inhibitors in women. However, due to the known role of DHT in male sexual differentiation, 5α-reductase inhibitors may cause birth defects such as ambiguous genitalia in the male fetuses of pregnant women. As such, they are not used in women during pregnancy. [36]
5α-Reductase inhibitors (5-ARIs), also known as dihydrotestosterone (DHT) blockers, are a class of medications with antiandrogenic effects which are used primarily in the treatment of enlarged prostate and scalp hair loss. They are also sometimes used to treat excess hair growth in women and as a component of hormone therapy for transgender ...
The pathway from progesterone (P4) to DHT is similar to that described above from 17OHP to DHT, but the initial substrate for 5α-reductase is P4 rather than 17OHP. Placental P4 in the male fetus is the feedstock, that is, a starting point, the initial substrate, for the backdoor pathway found operating in multiple non-gonadal tissues.
In addition to the lack of research showing the benefits of testosterone for women, taking the hormone can also come with side effects, including unwanted hair growth, acne, liver damage, hair ...
If SRY exists, then the gonads develop as testes, and commence the production of androgen hormones, mainly testosterone, dihydrotestosterone (DHT) and androstenedione; production of testosterone and conversion into dihydrotestosterone during weeks 6 to 12 of pregnancy are key factors in the production of a male fetus's penis, scrotum and ...
3. Medications. Some medications have been associated with temporary hair loss. Most of the time hair loss related to medication is due to the drug disrupting the hair growth cycle leading to a ...
Dihydrotachysterol (DHT) is a synthetic vitamin D analog activated in the liver that does not require renal hydroxylation like vitamin D 2 (ergocalciferol) and vitamin D 3 (cholecalciferol). DHT has a rapid onset of action (2 hours), a shorter half-life, and a greater effect on mineralization of bone salts than does vitamin D. [ 1 ]
In 2002, the Women's Health Initiative study (WHI) that was designed to demonstrate additional benefits of conventional hormone therapy (study participants were given Prempro or a placebo) was terminated prematurely after preliminary data indicated small increases in the risks of breast cancer, heart attack and stroke in older women using ...